Navigation Links
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
Date:5/7/2009

for efficacy as a twice-a-day and once-a-day drop respectively.

In a separate poster presentation titled "Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing at 8 Hours Following Dosing in a Multi-Site Clinical Trial Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis", ISTA demonstrated positive results from a multi-center, double-masked, placebo-controlled, clinical study with 86 patients who were randomized to receive either Bepreve 1.5% or placebo in both eyes in three CAC tests spaced two weeks apart. The results showed Bepreve 1.5% was statistically superior to placebo for at least 8 hours after ophthalmic dosing for reducing CAC-induced tearing.

In another poster presentation titled "The Safety of the Anti-Histamine Bepotastine Besilate Ophthalmic Solution in a Healthy Pediatric Population from Ten to Seventeen Years of Age", ISTA demonstrated Bepreve 1.5% dosed in both eyes twice daily for six weeks was safe in a healthy pediatric population from 10-17 years of age. The pediatric subjects in this age group (n = 45) were among 861 patients enrolled in this masked, randomized, placebo-controlled clinical trial, with a randomization of 2:1 (Bepreve 1.5%:placebo). The proportion of subjects in the Bepreve 1.5% treatment group with an adverse event (22.5%) was very similar to that seen for subjects instilling placebo (20.0%). No serious adverse events were reported during the clinical trial for any pediatric subject.

Earlier in the week, the Company presented additional results from clinical studies with Bepreve 1.0%, as well as data from a clinical study with the Company's Xibrom(TM) (bromfenac ophthalmic solution 0.09%) product and laboratory results with Vitrase(R) (hyaluronidase injection). The results were presented in the following poster presentations:

Bepotastine Besilate Ophthalmic Solution 1.0% Rapidly Reduces Conjunctival
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  IRIDEX Corporation (Nasdaq: IRIX ) today ... granted the Company a patent for a new proprietary ... eye surgery. The iClip Closure Device will initially be ... a broader range of ophthalmic surgical procedures in the ... procedure used in the treatment of glaucoma to drain ...
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone palmitate, ... relapse compared to placebo in patients with schizophrenia, ... published this week in the Journal ... . Results of the study served ... Application (NDA) filing for three-month paliperidone palmitate injection ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning ... certain statements issued by the Company in connection with ... information, GO TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact ... jlevi@zlk.com or by telephone at (212) 363-7500, ...
Breaking Medicine Technology:IRIDEX Granted U.S. Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 ... promotion on Invisalign. Eligible patients will receive $200 off ... are not particularly interested in wearing a mouthful of ... team, “The use of traditional braces is effective for ... who are already concerned with their oral appearance. The ...
(Date:3/30/2015)... Valerie Harper, the actress best known as ... Mary Tyler Moore Show,” will be the keynote speaker ... magazine announced today. Harper, who is living with terminal ... 40th Annual Congress on April 23 in Orlando, Fla. ... play in the lives of people with cancer. Nominated ...
(Date:3/30/2015)... 2015 GenSight ®, provider of ... as a leader in The Forrester Wave™: Strategic Planning ... , The independent report positions GenSight as a leader ... out of 5) for the analytics, corporate strategy, assessment, ... to GenSight’s position in the Leaders category. , According ...
(Date:3/30/2015)... 30, 2015 In an email sent ... of Oak Ridge, TN Community Development Department, announced: “I ... to traditional LBP work”. , ECOBOND® ... lead paint solution and surpasses other lead paint products ... that seals and treats lead dust and lead in ...
(Date:3/30/2015)... Software applications from five global ... second AS4 test and certification event, announced today ... interoperability software testing. New software applications from Axway, ... in this vendor-neutral test event which began in ... certifications for IBM, Oracle and Software AG, joining ...
Breaking Medicine News(10 mins):Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:ECOBOND® Selected to Protect School Children in Oak Ridge Tennessee in Lead Based Paint Remediation Project. 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... Award Recognizes Campaign to Vaccinate 1.2 Million Americans - ... and MinuteClinic, CVS Caremark,s retail clinic division, have received ... for a Corporate Campaign. The award, co-sponsored by ... Control and Prevention, was presented yesterday evening in Dallas ...
... found evidence that chronic disease in either a mother ... that are associated with the development of polycystic ovarian ... that brothers of women with PCOS and insulin resistance ... or diabetes, suggesting that factors associated with the condition ...
... Additional research is called for and patients with moderate ... to reduce their risk of atherosclerotic cardiovascular disease (CVD), ... The American Journal of Cardiology and ... issue of The American Journal of Cardiology ...
... CA, June 30 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., ... Inc. of San Diego California, announced the development of a ... Systems, Inc. (CBMS). , Age-Related Macular Degeneration (AMD) is the ... of age. The incidence of AMD in persons aged 55 ...
... FHCO ) today announced that it has been added ... Group reconstituted its comprehensive set of U.S. and global equity indexes ... Index is comprised of companies 1001 through 3000 within the ... cap companies. "We are very pleased to learn that The ...
... tackles lack of information about the disease in the Hispanic ... comic strip "Baldo" will feature a storyline on diabetes in ... disease among Hispanics. , The comic strip features a Hispanic ... will begin June 30, Baldo will learn his father has ...
Cached Medicine News:Health News:CVS/pharmacy and MinuteClinic Receive Award of Excellence from National Influenza Vaccine Summit 2Health News:CVS/pharmacy and MinuteClinic Receive Award of Excellence from National Influenza Vaccine Summit 3Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 2Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 3Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 4Health News:Patients with moderate to severe periodontitis need evaluation for heart disease risk 2Health News:Canadian Bio Med Attacks World's Leading Cause of Blindness 2Health News:The Female Health Company Added to Russell 2000(R) Index 2Health News:The Female Health Company Added to Russell 2000(R) Index 3
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Medicine Products: